מחיר לרווח עתידי: Tenaya Therapeutics (TNYA)

לוגו גרפי של Tenaya (TNYA)

This chart for Tenaya Therapeutics (TNYA) on the GURU.Markets platform demonstrates a Forward P/E of 0.00. The business relies on developing gene therapies for hereditary cardiomyopathies; however, a high probability of test failure and the threat of funding shortages make the project's commercial success debatable. Tenaya Therapeutics (TNYA) aims to regenerate heart tissue by correcting genetic defects at the cellular level.

TNYA - מכפיל P/E עתידי Tenaya Therapeutics, Inc. בטווח 04.07.2022 - 17.11.2026

פילוחים אנליטיים של חברת Tenaya Therapeutics

הערכת שווי פונדמנטלית:Tenaya Therapeutics, Inc. TNYA
פריט של המותג tenayatherapeutics.com

Forward P/E determines the business value relative to expected annual earnings. The ratio is calculated by dividing the current market capitalization by projected financial results. By analyzing the future P/E trajectory of a company, an investor assesses the market discount and growth potential. For Tenaya Therapeutics (TNYA), this indicator reflects market expectations regarding the commercialization of gene therapy. A diversified research pipeline mitigates risks, stabilizing the calculated values of the multiple.